Monday, April 10, 2017

US LED Lighting Market Outlook to 2021: Ken Research

The report titled “US LED Lighting Market Outlook to 2021- Demand for Energy Efficient Lighting and Government Initiatives to Lighten the Future” provides a comprehensive analysis of LED Lighting market in US. The report focuses on various aspects such as market size of US LED lighting industry by revenue generated and production volume and market segmentation by lamps, bulbs, luminiaries, by utility and by distribution channels. The report covers a detailed overview on trade scenario for Light emitting diodes of US with other countries. The report also describes about major trends and developments, issues and challenges and government role and initiatives that have influenced the market to a large extent. This publication helps the readers to understand the cost analysis for LED Lighting in US as well as recent technologies related to US LED Lighting.  Competition prevailing in the sector along with detailed company profiles has been thoroughly covered in the report. The report concludes with market projection for future and analyst recommendation highlighting the major opportunities and cautions.
US Led Lighting Market
LED Lighting Market in US
The LED lighting market of the US has witnessed a rapid growth over the recent past. Technological advancements in the market have been the major reason responsible for growing product lines of LED lights in the country. The growing concern among the population about the amount of heat emitted by traditional fluorescent lights has made people shift to more energy saving resources, thereby expanding the overall size of LED lighting market in the country from USD ~ million in 2011 to USD ~ million during 2016.
Market Segmentation
By Type of LED: Lower initial cost and ease of installation of LED lamps have made lamps to dominate the market, contributing ~% of the revenue to the total revenues of US LED market in 2016. LED luminaires have been successful in driving the overall LED lighting market of the US by increasing their revenue share from ~% in 2014 to ~% in 2016. The traditional use of incandescent bulbs has been replaced by the use of LED reflectors, contributing revenue share of ~% to the overall market from the sale of LED lamps. LED tubes and other LEDs typically including simple bulbs contributed ~% and ~% share to the revenues of LED lamps in the US. LED luminaires which include downlights, troffers, roadway fixtures, outdoor area lights and other luminaires generated revenues worth USD ~ million, USD ~ million, USD ~ million, USD ~ million and USD ~ million revenues respectively in the LED lighting market of the US during 2016.
By Application of LED Lights: The increased demand for directional LEDs by shopping malls to showcase their products and their use in flood lights, made this segment dominate the LED market with revenue share of ~% in the overall sales of LED lights during 2016. Following directional LEDs, A-Type LEDs generated revenue of USD ~ million in 2016. LED linear fixtures and building exteriors contributed ~% and ~% of the revenues respectively in 2016. The dimming requirements and high color quality provided by decorative LEDs has enabled the segment to garner revenues worth USD ~ million during 2016. Further, LED for parking garage, Roadway LED, Small Directional LED, Parking lot LED and High/Low Bay LED contributed ~%, ~%, ~%, ~% and ~% respectively to the total revenues of LED lights in 2016.
By Usage (Indoor LEDs and Outdoor LEDs): Outdoor LEDs have contributed ~% to the revenues of LED lights in 2016. Indoor LEDs which are used in commercial, residential and industrial sector have contributed ~%, ~% and ~% share to the total sales of indoor LED lights in the US during 2016. Outdoor LEDs that are used in building exteriors, parking garage, roadway and parking lots contributed ~%, ~%, ~% and ~% share in revenues during 2016
Competitive Landscape
US LED lighting market is highly concentrated with the presence of few leading lighting manufacturers in the country. Since the sector requires large amount of capital to be invested, this has inhibited the emergence of several companies in the space. Frequent introduction of new LED products, rapid changes in technology, changing customer requirements, short product life cycles and prices of similar technology by various companies are common platforms on which the competition prevails in the overall lighting market of the US. Lighting companies such as Cree, Acuity brands, Copper Lighting division of Eaton Corporation, general electric company, Hubbell Incorporated, Philips and Osram are the major competitors in the market.
Future Analysis and Projections
The US LED lighting market is expected to grow at a robust CAGR of ~% from 2016 to 2021 owing to rising number of market players, increasing awareness about online energy saving lights among customers, and growing efforts of government to shift customers towards LED lights. The LED lighting market will witness launch of innovative LED products being introduced in the market which will lead to an increase in demand by the population, thus making the LED industry contribute a larger share to the total economy.
Key Topics Covered in the Report:
Overview and Genesis for the US LED Lighting Market
Comparative Analysis for the US LED Lighting Market with Global Market
US LED Lighting Market Value Chain Analysis
US LED Lighting Market Size, 2011-2016
US LED Light Market Segmentation
Trade Scenario for the US LED Lighting Market
Cost Analysis for LED Lighting in the US Market
Decision Making Process before Purchasing LED Lighting in the US Market
Trends and Developments in the US LED Lighting Market
Issues and Challenges in US LED Lighting Market
SWOT Analysis for the US LED Lighting Market
Recent Technologies in US LED Lighting Market
Manufacturing Clusters for LED and Component Manufacturers in the US
Government Initiatives and Regulations in the US LED Lighting Market
Competitive Scenario in US LED Lighting Market
Competitive Landscape of Major Players in US LED Lighting Market
US LED Lighting Market Future Outlook and Projections
Macroeconomic Indicators Affecting US LED Lighting Market
For more coverage click on the link below:
Related Reports
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249

Friday, April 7, 2017

Diabetes & Obesity Drug Development Pipeline Review 2016: Ken Research

The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications. While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development.
Diabetes and Obesity Drug Development Market
The combined therapy area of diabetes and obesity presents a strong pipeline, accounting for a large proportion of the overall metabolic disorders therapy area. The majority of products are small molecules and biologics, which reflects the overall pharmacotherapeutic market trend.
An increasing pipeline presence for obesity-indicated products and overwhelming global media interest highlight the relevance of this indication and its future potential global revenues. However, the number of pharmacotherapeutic products for obesity is dwarfed by diabetes-indicated products. Given the status of obesity as a risk factor for T2DM, it is likely that the T2DM pipeline will continue to grow with the rising obesity incidence.
Key topics covered in report
Diabetes and Obesity Drug Development Size
Diabetes and Obesity Drug Development Share
Diabetes and Obesity Drug Development Trends
Diabetes and Obesity Drug Development Growth
Diabetes and Obesity Drug Development Outlook
Diabetes and Obesity Drug Development Analysis
Diabetes and Obesity Drug Development Research
Diabetes and Obesity Drug Development Revenue
Diabetes and Obesity Drug Development Research Report
For more coverage click on the link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022-Growth Driven By Increasing Treatment-Receiving Pool: Ken Research

Hemophilia is a rare disease affecting more than 400,000 people worldwide. Hemophilia A is four times as common as hemophilia B, and more than half of patients with hemophilia A have a severe form of hemophilia. Males have a much higher chance of developing hemophilia because they only receive one copy of the X chromosome from their mother.
Hemophilia A and B Therapeutics Market
The mainstay of treatment for hemophilia is to replace the missing factor VIII or factor IX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to factor VIII or factor IX treatment and need a bypassing agent, such as factor VIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative market opportunity.
The current marketed products landscape comprises replacement factor therapies, such as recombinant therapies and new long-acting recombinant products. The current pipeline shows strong promise, as it shows a gradual shift from short-acting recombinant factor VIII or factor IX to long-acting recombinant factor VIII, and from factor replacement therapies to non-factor therapies. Nevertheless, significant unmet need remains for products that can avoid the development of inhibitors in patients with hemophilia.
Though late-stage pipeline for treatment of hemophilia seems promising, the main market restraint is likely to be low penetration of new long-acting recombinant therapies in India and China, owing to their high expected prices.
Key topics covered in report
Hemophilia A and B Therapeutics Market Size
Hemophilia A and B Therapeutics Market Share
Hemophilia A and B Therapeutics Market Trends
Hemophilia A and B Therapeutics Market Growth
Hemophilia A and B Therapeutics Market Outlook
Hemophilia A and B Therapeutics Market Analysis
Hemophilia A and B Therapeutics Market Research
Hemophilia A and B Therapeutics Market Revenue
Hemophilia A and B Therapeutics Market Research Report
For more coverage click on the link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249

Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized By Emerging Biologic Therapies: Ken Research

Disease and disorders involving the gastrointestinal system are among the most common conditions encountered worldwide, and many of them can have a significant impact on quality of life. The direct and indirect socio-economic burden associated with gastrointestinal disorders is profound. The direct costs of medical consultations and treatments in the US for gastroesophageal reflux disease alone are estimated to amount to $9.3 billion, while the indirect costs due to absenteeism and impairment in work performance total $75 billion (Chait, 2010).
Global Gastrointestinal Drug Market
Despite the significant global socio-economic burden, many gastrointestinal disorders are still poorly understood, and there is a significant unmet need for novel, safe and effective therapies, as treatment options are often lacking, causing many patients to be dissatisfied with their treatment. The unmet need and demand for better treatments and the high prevalence of digestive conditions make the gastrointestinal market an attractive candidate for therapeutic development.
This report covers all gastrointestinal disorders, but there is a particular focus on three key diseases: gastroesophageal reflux disease, irritable bowel syndrome and inflammatory bowel disease. The global gastrointestinal market was valued at $35.7 billion in 2015 and is projected to grow at a compound annual growth rate (CAGR) of 4.45%, reaching $48.4 billion in 2022. Proton pump inhibitors (PPIs) and tumor necrosis factor (TNF)-? inhibitors generate the largest revenues and continue to retain commercial prominence. Key drivers of market growth will be the uptake of recently approved premium products, rising prevalence, and promising late-stage products, including a number of biologic therapies that are expected to be highly valuable.
Key topics covered in report
Global Gastrointestinal Therapeutics Drug Market Size
Global Gastrointestinal Therapeutics Drug Market Share
Global Gastrointestinal Therapeutics Drug Market Trends
Global Gastrointestinal Therapeutics Drug Market Growth
Global Gastrointestinal Therapeutics Drug Market Outlook
Global Gastrointestinal Therapeutics Drug Market Analysis
Global Gastrointestinal Therapeutics Drug Market Research
Global Gastrointestinal Therapeutics Drug Market Revenue
Global Gastrointestinal Therapeutics Drug Market Research Report
For more coverage click on the link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249

Global Diabetes and Obesity Drugs Market to 2022-Insulins and GPCRs Retain Commercial Prominence: Ken Research

Diabetes is a chronic metabolic disease characterized by hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia in diabetic patients is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM). Obesity, meanwhile, is defined as abnormal or excessive body fat accumulation that presents a risk to health.
Global Diabetes Therapeutics Market
A current global rise in T2DM prevalence is intrinsically linked with the current global rise in obesity. The rapidly increasing global obesity prevalence has resulted in it being considered a global epidemic, and there is a vast and growing global patient population potentially requiring pharmacotherapeutic treatment.
Historically anti-obesity therapeutics have been out of favor due to safety concerns. Both diabetes and obesity products are commonly associated with cardiovascular adverse events, and this is further compounded by concerns relating to cancer development through long-term usage of anti-obesity products. This has resulted in an unmet need for products with favorable safety and efficacy profiles, particularly in the case of obesity.
The market size for the diabetes and obesity disease cluster is set to increase considerably, driven by the success of a number of T2DM pipeline products, and a rapidly expanding global patient population. However, obesity pipeline activity is set to remain markedly low, despite a patient population of epidemic proportions.
Key topics covered in report
Global Diabetes Therapeutics Market Size
Global Diabetes Therapeutics Market Share
Global Diabetes Therapeutics Market Trends
Global Diabetes Therapeutics Market Growth
Global Diabetes Therapeutics Market Outlook
Global Diabetes Therapeutics Market Analysis
Global Diabetes Therapeutics Market Research
Global Diabetes Therapeutics Market Revenue
Global Diabetes Therapeutics Market Research Report
For more coverage click on the link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249

Global Antibacterial Drugs Market to 2022: Ken Research

The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market. This report considers the key developments in this market, with particular focus on drugs indicated for use in pneumonia, methicillin-resistant staphylococcus aureus (MRSA), sepsis and tuberculosis.
Global Antibacterial Drug Market
Drugs for the prevention of bacterial infections are typically vaccines, which help to train the body's immune system to fight off specific infections, and can therefore help to prevent infections of certain bacterial strains. However, several prophylactic monoclonal antibodies are also currently in development.
Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, which include the very widely prescribed penicillin. However, bacteria have developed resistance to penicillin by producing beta-lactamase enzymes that break open the beta-lactam ring found in these antibiotics, rendering them ineffective. As a result modern beta-lactams are frequently combination drugs of a beta-lactam and a beta-lactamase inhibitor.
In addition to beta-lactams there are several other classes of drugs used to treat bacterial infections. These include fluoroquinolones, which inhibit DNA gyrase and/or topoisomerase IV; and protein synthesis inhibitors, which have applications within the treatment of bacteria that are resistant to beta-lactam antibiotics. However, bacterial resistance has also developed against these drugs, and as such there is a gap in the market for a new generation of drugs that are effective against drug-resistant bacteria.
The antibacterial market is currently dominated by vaccines, in particular those for the prevention of pneumococcal infections, diphtheria, tetanus and pertussis. However, recent years have seen key additions in the form of therapies for antibiotic-resistant bacteria, including strains with multi-drug resistance. The number of such products is expected to increase drastically between 2016 and 2022.
Key topics covered in report
Global Antibacterial Drug Market Size
Global Antibacterial Drug Market Share
Global Antibacterial Drug Market Trends
Global Antibacterial Drug Market Growth
Global Antibacterial Drug Market Outlook
Global Antibacterial Drug Market Analysis
Global Antibacterial Drug Market Research
Global Antibacterial Drug Market Revenue
Global Antibacterial Drug Market Research Report
For more coverage click on the link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249